Three days of reckoning for checkpoint blockers
Planning for this week’s three-day adcom on US accelerated approvals for anti-PD-(L)1 drugs? Here’s the background info you need.
The biotech resurrection continues
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
Thinking the unthinkable on Covid vaccine approvals
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
Crisis, what crisis? Curevac denies everything
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
